25
Orally Bioavailable and Brain Penetrant Mps1/TTK inhibitors as cancer therapeutics
The Ohio State University
Small molecule
Oncology
Hit To Lead or Lead Optimization
Upregulation of the mitotic kinase Mps1/TTK correlates to aggressive phenotypes in both solid and hematological malignancies. Researchers at Ohio State have discovered an orally bioavailable and brain penetrant Mps1/TTK inhibitor that exhibits single agent tumor growth inhibition in a murine xenograft model of human triple-negative breast cancer (TNBC) upon daily administration.
US 2019-0106422 A1